Related Experiment Video

Updated: Sep 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination ACE inhibitors and angiotensin II receptor blockers for hypertension

Patrick M Finnegan1, Brenda L Gleason

  • 1St. Louis College of Pharmacy, St. Louis, MO 63110-1088, USA.

The Annals of Pharmacotherapy
|May 30, 2003
PubMed

Insights

Combined angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) therapy for hypertension shows statistically significant blood pressure reduction. However, clinical significance is lacking, and more trials are needed for recommendation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors offer incomplete renin-angiotensin system blockade.
  • This can lead to diminished blood pressure control in some hypertensive patients.
  • Angiotensin II receptor blockers (ARBs) may offer additive blood pressure reduction.

Purpose of the Study:

  • To review existing data on the efficacy of combined ACE inhibitor and ARB therapy.
  • To evaluate the use of this combination for managing essential hypertension.

Main Methods:

  • Comprehensive literature search of MEDLINE, IPA, and EMBASE databases.
  • Searched for studies published between 1966 and April 2003.
  • Utilized keywords: ACE inhibitor, ARB, essential hypertension, combination therapy.

Main Results:

  • Studies demonstrated statistically significant reductions in blood pressure with combined ACE/ARB therapy.
  • The renin-angiotensin system blockade was more complete with the combination.
  • However, the clinical significance of these blood pressure reductions was not clearly established.

Conclusions:

  • Combined ACE inhibitor and ARB therapy achieves statistically significant blood pressure reduction.
  • The clinical benefit and significance of this combination therapy require further investigation.
  • Additional clinical trials are necessary before recommending routine use of ACE/ARB combination therapy for hypertension.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...